A new study on epigenetic reprogramming shows it is not as simple as we hoped. Three human cell types, reprogrammed part of the way, then watched to see if they came back. The artery cells did. The immune cells only came back from shallow reprogramming. And the skin cells scored younger on the clock while still not being able to divide properly.
The paper: Washizu, Wang, Draper, Yamanaka and Kunitomi. bioRxiv, 12 November 2026.
Partial reprogramming is therapeutically useful only if cells keep its benefits while recovering their lineage identity and function after the reprogramming factors are withdrawn. Whether the relationship between reprogramming depth and recovery differs between lineages is unknown. Using reversible, traceable Sendai-OSKM, we prospectively isolated intermediate reprogramming states from primary human fibroblasts, cytotoxic T cells, and aortic endothelial cells and followed their recovery. Outcomes diverged: fibroblasts kept a reduced DNA methylation age but retained stromal remodeling and incomplete proliferative recovery; T cells recovered only from shallow reprogramming, with enhanced effector function; endothelial cells rapidly recovered identity, kept a reduced methylation age, and markedly improved vascular function. None of this tracked iPSC derivation efficiency. Multiome and knockdown analyses identified TOX as a shared progression dependency, whereas its candidate downstream programs were predominantly lineage-specific. Partial reprogramming involves a lineage-specific tradeoff between rejuvenation and recovery that must be optimized one lineage at a time.
K.W., S.Y., and A.K. are co-inventors on a patent describing a method for rejuvenation of human somatic cells. S.Y. is an unpaid scientific advisor to iPS Academia Japan, Inc., Orizuru Therapeutics, Inc., and Altos Labs, Inc., and a member of the Cell Press Advisory Board. The remaining authors declare no competing interests.
Altos Labs, https://ror.org/05467hx49






